Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. [electronic resource]
Producer: 20200305Description: 77-87 p. digitalISSN:- 1097-6744
- Adrenergic beta-Antagonists -- economics
- Aspirin -- economics
- Atenolol -- economics
- Budgets
- Cardiovascular Diseases -- economics
- Cost Savings
- Cost-Benefit Analysis
- Drug Combinations
- Drug Costs
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- economics
- Life Expectancy
- Male
- Medication Adherence
- Middle Aged
- Nutrition Surveys
- Platelet Aggregation Inhibitors -- economics
- Ramipril -- economics
- Renin-Angiotensin System
- Secondary Prevention -- economics
- Stroke -- economics
- United States
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.